Savient Pharmaceuticals' Asset Sale

Savient Pharmaceuticals raised a round of funding on January 10, 2014. Investors include Crealta Pharmaceuticals.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients who do not respon…

Articles about Savient Pharmaceuticals' Asset Sale: